Le Lézard
Classified in: Health, Business
Subjects: CCA, ERP

DarioHealth to Host Third Quarter 2019 Conference Call October 28, 2019


NEW YORK and CAESAREA, Israel, Oct. 17, 2019 /PRNewswire/ -- Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: DRIO) today announced it will release its third quarter 2019 results on Monday, October 28, and host a conference call the same morning at 9:00 am EDT.

Dario Health (PRNewsfoto/DarioHealth Corp.)

The Company will discuss its third quarter 2019 operating and financial results and its outlook for 2019.

The call will be hosted by Erez Raphael, Chief Executive Officer, Olivier Jarry, President and Chief Commercial Officer, and Zvi Ben-David, Chief Financial Officer.

The live call can be accessed by dialing 1-844-369-8770 or 1-862-298-0840 (international). Participants should ask for the DarioHealth Earnings Conference Call. The conference call will also be available via live webcast at: https://www.investornetwork.com/event/presentation/54487

Conference Call Details:

Date: Tuesday, October 28, 2019

Time: 9:00am EDT

Dial-in Number: 1-844-369-8770

International Dial-in Number: 1-862-298-0840

Webcast: https://www.investornetwork.com/event/presentation/54487

Participants are asked to dial-in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion through November 11, 2019. To listen to the replay, dial 1-877-481-4010 (domestic) or 1-919-882-2331 (international) and use replay passcode 54487. The webcast replay will be available through January 28, 2020.

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ: DRIO) is a leading Global Digital Therapeutics (DTx) company revolutionizing the way people manage their health across the chronic condition spectrum. By delivering evidence-based interventions that are driven by precision data analytics, high quality software, and personalized coaching, DarioHealth have developed a novel approach that empowers individuals to adjust their lifestyle in a unique and holistic way. DarioHealth's cross functional team operates at the intersection of life science, behavioral science, and software technology to deliver seamlessly integrated and highly engaging therapeutic interventions. Already one of the highest rated diabetes solutions, its user-centric approach is loved by tens of thousands of customers around the globe. DarioHealth is rapidly expanding solutions for additional chronic conditions such as hypertension and moving into new geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions via the Dario mobile app, please go to: https://www.dariohealth.com/.

Logo: http://mma.prnewswire.com/media/544126/DarioHealth_Logo.jpg

DarioHealth Corporate Contact:
Claudia Levi
Content & Communications Manager
[email protected]
+1-347-767-4220

SOURCE DarioHealth Corp.


These press releases may also interest you

at 17:00
Zepp Health Corporation ("Zepp" or the "Company") , a global leader in smart wearables and health technology, today announced that it has received a letter from the New York Stock Exchange (the "NYSE") dated April 30, 2024, notifying Zepp that it is...

at 16:55
Revelation Biosciences, Inc. (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March...

at 16:55
Maple Counseling has partnered with Saban Community Clinic to launch the Saban Partnership Program, aimed at enhancing access to mental healthcare for underserved communities. This initiative includes the introduction of four bilingual Associate...

at 16:35
Bristol Myers Squibb today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC). CheckMate -73L evaluated...

at 16:35
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung...

at 16:35
Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a...



News published on and distributed by: